Published in Virology on June 20, 2005
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst (2010) 3.88
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst (2009) 3.77
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer (2009) 3.33
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2009) 3.15
Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.91
Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol (2009) 2.74
Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog (2006) 2.65
Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol (2007) 2.27
High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer (2007) 2.06
The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev (2010) 1.94
A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res (2010) 1.82
Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One (2011) 1.80
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
Management of low-grade cervical lesions in young women. CMAJ (2005) 1.69
Detection of precancerous cervical lesions is differential by human papillomavirus type. Cancer Res (2009) 1.67
Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J Clin Microbiol (2011) 1.65
A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis (2007) 1.62
A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev (2008) 1.53
Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res (2010) 1.50
Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol (2006) 1.46
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin (2011) 1.46
Human papillomavirus genome variants. Virology (2013) 1.45
Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.42
Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst (2012) 1.40
Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis (2011) 1.40
How to evaluate emerging technologies in cervical cancer screening? Int J Cancer (2009) 1.37
Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer (2009) 1.37
Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology (2009) 1.36
Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol (2008) 1.35
Phylogenetic incongruence among oncogenic genital alpha human papillomaviruses. J Virol (2005) 1.34
Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. AIDS (2011) 1.32
HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer (2007) 1.30
Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer (2011) 1.25
Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer (2012) 1.23
An armamentarium of wart treatments. Clin Med Res (2006) 1.23
The evolving definition of carcinogenic human papillomavirus. Infect Agent Cancer (2009) 1.23
Sequence imputation of HPV16 genomes for genetic association studies. PLoS One (2011) 1.20
Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics (2009) 1.18
Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer (2011) 1.17
Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages. Acta Dermatovenerol Alp Pannonica Adriat (2011) 1.14
Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health (2015) 1.13
The E5 proteins. Virology (2013) 1.11
Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity. PLoS One (2010) 1.09
The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev (2009) 1.09
Multiple-type human papillomavirus (HPV) infections: a cross-sectional analysis of the prevalence of specific types in 309,000 women referred for HPV testing at the time of cervical cytology. Int J Gynecol Cancer (2013) 1.08
Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer (2009) 1.08
Genomic diversity and interspecies host infection of alpha12 Macaca fascicularis papillomaviruses (MfPVs). Virology (2009) 1.08
Human papillomavirus genotyping after denaturation of specimens for Hybrid Capture 2 testing: feasibility study for the HPV persistence and progression cohort. J Virol Methods (2007) 1.05
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One (2013) 1.04
Human papillomavirus type 58: the unique role in cervical cancers in East Asia. Cell Biosci (2012) 1.03
Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis (2010) 1.03
Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol J (2011) 1.02
Characterization and experimental transmission of an oncogenic papillomavirus in female macaques. J Virol (2007) 1.02
The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification. J Virol (2010) 1.02
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis (2013) 1.00
HIV Infection Alters the Spectrum of HPV Subtypes Found in Cervical Smears and Carcinomas from Kenyan Women. Open Virol J (2013) 0.99
Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC Infect Dis (2013) 0.97
Persistence of concurrent infections with multiple human papillomavirus types: a population-based cohort study. J Infect Dis (2011) 0.95
Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis. PLoS One (2011) 0.95
Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study. Cancer Res (2010) 0.93
The increasing frequency of cervical cancer in Korean women under 35. Cancer Res Treat (2008) 0.93
Human papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species. Cancer Epidemiol Biomarkers Prev (2009) 0.93
Disrupted human-pathogen co-evolution: a model for disease. Front Genet (2014) 0.92
Identification and characterization of two novel human papillomaviruses (HPVs) by overlapping PCR: HPV102 and HPV106. J Gen Virol (2007) 0.92
Human papillomavirus persistence in young unscreened women, a prospective cohort study. PLoS One (2011) 0.92
Analysis of host-parasite incongruence in papillomavirus evolution using importance sampling. Mol Biol Evol (2010) 0.92
Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis (2011) 0.92
Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol (2006) 0.92
Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol (2011) 0.90
Inactivation of p53 rescues the maintenance of high risk HPV DNA genomes deficient in expression of E6. PLoS Pathog (2013) 0.90
Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. Int J Cancer (2009) 0.90
Association between hTERT activation by HPV E6 proteins and oncogenic risk. Virology (2012) 0.89
Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study. J Clin Microbiol (2013) 0.89
Immunosuppression facilitates the reactivation of latent papillomavirus infections. J Virol (2013) 0.89
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Long-term cumulative detection of human papillomavirus among HIV seropositive women. AIDS (2014) 0.88
Papillomaviruses: evolution, Linnaean taxonomy and current nomenclature. Trends Microbiol (2010) 0.87
Physical state and viral load as predictive biomarkersfor persistence and progression of HPV16-positive cervical lesions: results from a population based long-term prospective cohort study. Am J Cancer Res (2012) 0.86
HPV in HIV-Infected Women: Implications for Primary Prevention. Front Oncol (2014) 0.86
Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiol (2008) 0.86
Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studies. BMC Infect Dis (2013) 0.86
Human papillomavirus genomics: past, present and future. Curr Probl Dermatol (2014) 0.85
Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev (2014) 0.85
Performance evaluation of manual and automated (MagNA pure) nucleic acid isolation in HPV detection and genotyping using Roche Linear Array HPV Test. Infect Dis Obstet Gynecol (2011) 0.84
Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females. PLoS One (2012) 0.84
A Suggested Approach to Simplify and Improve Cervical Screening in the United States. J Low Genit Tract Dis (2016) 0.84
Detection of Human Papilloma Virus (HPV) in oral mucosa of women with cervical lesions and their relation to oral sex practices. Infect Agent Cancer (2010) 0.83
Evolution of human papillomavirus carcinogenicity. Adv Virus Res (2010) 0.83
Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland. Br J Cancer (2013) 0.83
Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer. J Clin Microbiol (2011) 0.83
Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer (2013) 0.82
Genetic variability and phylogeny of high risk HPV type 16, 18, 31, 33 and 45 L1 gene in Greek women. Int J Mol Sci (2011) 0.82
A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo. Br J Cancer (2010) 0.82
Factors influencing histologic confirmation of high-grade squamous intraepithelial lesion cytology. Obstet Gynecol (2008) 0.82
Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing. Br J Cancer (2012) 0.81
Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections. J Infect Dis (2009) 0.81
Laboratory and clinical aspects of human papillomavirus testing. Crit Rev Clin Lab Sci (2012) 0.80
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Replicating genotype-phenotype associations. Nature (2007) 16.11
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86
Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet (2010) 9.07
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology (2010) 7.24
Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med (2005) 6.72
2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol (2007) 6.25
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin (2002) 5.56
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev (2004) 5.32
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
The Diesel Exhaust in Miners study: a nested case-control study of lung cancer and diesel exhaust. J Natl Cancer Inst (2012) 5.27
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA (2005) 5.12
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet (2005) 5.01
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA (2007) 4.66
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst (2007) 4.55
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions. Am J Hum Genet (2006) 4.40
Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA (2002) 4.39
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A (2008) 4.06
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst (2009) 3.77
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol (2004) 3.67
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol (2011) 3.66
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis (2005) 3.50
High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol (2011) 3.49
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Population substructure and control selection in genome-wide association studies. PLoS One (2008) 3.44